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A previously described nitroglycerin-induced heparin resistance could not be verified by in-vitro experiments or in a
randomized, double-blind, crossover trial in healthy volunteers. A clinically relevant attenuation of the anticoagulant effect
of a heparin bolus (40 U.kg'1) by a concomitant infusion of nitroglycerin (100 fig.min~') was absent. Activated partial
thromboplastin time was not significantly different under nitroglycerin infusion as compared to placebo after heparin
injection. Concentrations and activities of antithrombin III and heparin cofactor II remained unchanged during nitro-
glycerin infusion. An interaction of these two frequently combined drugs in patients with active thromboembolic disease or
after a prolonged concomitant intravenous administration cannot be ruled out. Since this is of clinical importance, further
studies must clarify a possible nitroglycerin-induced heparin resistance.
Introduction
Anticoagulation with heparin is widely accepted in
patients with acute coronary heart disease or after
therapeutic interventions such as thrombolysis or coron-
ary angioplasty113'. The variable individual response to a
standard dose of heparin is well known'451. One possible
explanation may be an interaction of heparin with
co-administered drugs. In intensive care medicine,
heparin is frequently used in combination with a con-
tinuous infusion of nitroglycerin. Previous reports have
suggested an attenuation of the anticoagulant effect of
heparin induced by concomitantly infused nitroglycerin
preparations'6"81. Based on our own observations of
an increased need for heparin to maintain a therapeutic
state of systemic anticoagulation in several patients with
nitroglycerin infusions, this study examined a possible
nitroglycerin-induced heparin resistance in vitro and
with a randomized, double-blind, placebo-controlled
crossover trial in healthy volunteers.
Materials and methods
The preparation of nitroglycerin used was a 0-5%
solution of glycerol trinitrate in ethanol with poly-
oxyethylene-40-castoroil (2mg.mr ' ) as emulgator
(Trinitrosan, E. Merck, Darmstadt, Germany); the
heparin used was sodium heparinate (Liquemin, F.
Hoffmann-La Roche, Basel, Switzerland). Activated
partial thromboplastin time (APTT, s) was performed
according to the manufacturer (Aktin, Baxter Dade,
DOdingen, Switzerland). Values in normal adult plasma
range from 25-34 s, average 30 s. Heparin concentration
(U.ml ') was measured as anti-Xa-activity*91 using an
Submitted for publication on I October 1990, and in revised form 10 April
1991.
Correspondence R. A. Schoenenberger, MD, Departement of Internal
Medicine, Uni\ersity Hospital. Petersgraben 4, CH-4051 Basel Switzerland.
amidolytic assay (Coatest Heparin, Kabi Diagnostica,
Molndal, Sweden). For the amidolytic assay of anti-
thrombin-III-activity (AT Ilia, % of normal) bovine
thrombin and the chromogenic substrate chromozym
TH (Boehringer, Mannheim, Germany) were used'9101.
Immunoreactive antithrombin III (AT I Hi, % of normal)
was measured by a quantitative electroimmunoassay1"1
using a rabbit antiserum (Clottimmun-Antithrombin-III,
Behring, Marburg, Germany). Heparin-cofactor II (HC
II, % of normal) was measured as dermatan sulfate cofac-
tor activity*12131 after heparin neutralization by polybrene
(Hexadimethrin bromide, Aldrich-Europe, Belgium) in
the tris-EDTA-polybrene buffer (002 Tris, 015 M
NaCl, 00075 M K2EDTA, 0 1% PEG 6000, polybrene
2ug.ml-', 002% NaH3 pH 80) used for the 1:76
plasma predilution. In the test system dermatan sulfate
(334ug.ml~' final concentration) specifically acceler-
ated the heparin cofactor 11/thrombin reaction'14'. The
remaining free thrombin (human thrombin, Calbiochem,
Lucerne, Switzerland) was measured amidolytically on
chromozym TH. All amidolytic assays were run on a
centrifugal analyser (Cobas, Roche). To minimize test-
specific components of variability, all assays of heparin
concentration, AT Ilia, AT Illi, and HC II were per-
formed from deep frozen plasma samples in one single
run. In the range of values concerned, within-assay
coefficients of variance for APTT, AT Ilia, AT Illi,
HC II, and heparin concentration are 3%, 4%, 6%,
and 5%, respectively. The corresponding between-assay
coefficients of variance are 5%, 7%, 9%, 12%, and 11%.
IN VITRO STUDY
Heparin was added to pooled, platelet-poor citrate
plasma obtained from drug-free donors aiming at a
final concentration of 0-3 U.ml"1. Trinitrosan was
added, resulting in nitroglycerin concentrations from
001 ug.ml ' to lOOug.ml"1. In each sample coagulation
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Table I Coagulation parameters with increasing mlroglyccrin concentrations
Heparin added
(U.ml ')
0
0 3
0 3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
N G added
(lig.ml ')
0
H,O
ethanol
001
0 1
0-5
10
50
10
50
100
APTT
(s)
301
54-5
54-7
53-5
54-3
560
569
56-8
52-2
53-7
53 1
Heparin measured
(U.ml ')
0
0-39
0-38
0 34
0 33
0 33
0-34
0-31
0-35
0 39
0-29
A T Il ia
(%)
90-5
90-5
98
97
97
90
97
96
100
103
AT lll i
(%)
_
94
94
90
90
87
89
90
90
99
93
H C I I
(%)
_
108
115
110
117
93
98
104
97
103
100
A P T T . activated partial thromboplast in time; A T I l ia : activity of ant i thrombin III; AT lll i : concen-
t ra t ion of ant i thrombin III measured immunologically; H C II. activity of hepann-cofactor II; N G :
nitroglycerin concentrat ion.
assays were performed in duplicate. Control values were
obtained with aqua bidest and ethanol.
IN VITRO STUDY
Volunteers were male students (n = 7, mean age
28+4 years, weight 77+ 8 kg, platelet count 235 000 ±
54 000.ml"1) with no history of coagulation disorders or
thromboembolic disease. After obtaining baseline values
of coagulation parameters, nitroglycerin (100 ng.min"1)
and saline 0-9%, respectively, were infused in a rando-
mized, double-blind, crossover sequence. Fifteen minutes
after the start of the infusion 40U.kg~' heparin were
injected as a bolus. Five, 30, 60, 90, and I80min after
heparin injection, blood was drawn for coagulation tests.
Infusion and blood sampling were performed through
two different venous cannulas, one in each forearm. After
return of coagulation parameters to baseline values the
infusion was changed. After an equilibration period of
15 min the trial was repeated with the same volunteer.
The study was approved by the local review committee
for human research, and informed, written consent was
obtained from each volunteer.
Statistical evaluation was done by Student's t-test for
paired values and two-way analysis of variance. A two-
tailed /"-value of <005 was considered statistically
significant.
Results
In-vitro results are summarized in Table 1. Increasing
concentrations of nitroglycerin did not alter the anti-
coagulant effect of heparin monitored by prolongation of
APTT. Activity and concentration of AT HI and activity
of HC II remained unchanged. The nitroglycerin concen-
trations tested in vitro (001-100ug.ml"1) include and
exceed plasma concentrations achieved by doses clinically
used for intravenous therapy1151.
Average values of APTT after bolus injection of
heparin in seven healthy volunteers under a continuous
infusion of nitroglycerin (lOOug.min ') compared to
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Figure I Activated partial thromboplastin time (APTT) in seconds
under nitroglycerin infusion (100 ug.min ') compared to 0-9% saline
in seven healthy volunteers after a bolus injection of hepann
(40U.kg ')(mean±SD).
placebo are shown in Fig. 1. There was no significant
difference at any time APTT was measured. Baseline
values of APTT were identical, and peak values after
heparin were in the therapeutic range in all subjects.
Heparin concentration was not affected by the nitro-
glycerin infusion (Fig. 2). At no time did the activities of
antithrombin IN and heparin-cofactor II change under
nitroglycerin infusion (Fig. 3); the same was true for the
concentration of antithrombin III measured immuno-
logically (data not shown). No side effects from heparin
bolus injection or nitroglycerin infusion were observed.
Discussion
The clinical importance of an interaction of heparin
with infused nitroglycerin is evident. Frequent laboratory
testing and dose adjustments of heparin in patients under
nitroglycerin would be mandatory. The risk of bleeding
complications after discontinuation of a nitroglycerin
infusion would call for a dose reduction of heparin.
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Figure 2 Concentration of heparin under nitroglycorin infusion
(100 ug.min"1) compared to 0-9% saline in seven healthy volunteers
after a bolus injection of 40 U.kg'1 (mean ± SD).
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Figure 3 Activities of antithrombin III and heparin cofactor II
under nitroglycerin infusion (100 u£.min~')compared to 0-9% saline
in seven healthy volunteers after a bolus injection of heparin
(40U.lcg-')(mcan±SD).
A nitroglycerin-induced 'heparin-resistance' may be
explained by various mechanisms: (a) direct interaction
on a molecular basis (b) formation of a nitroglycerin-
plasmaprotein-complex inactivating the negatively
charged heparin like protamin (c) depletion of coagu-
lation inhibitors mediating the heparin effect (d) influence
on heparin elimination or metabolism by nitroglycerin.
The results presented do not support the assumption of
a clinically relevant nitroglycerin-induced heparin resist-
ance. The in-vitro results rule out a major direct
molecular interaction of the two drugs. The absence of an
alteration in extent or duration of the anticoagulant effect
of a heparin bolus monitored by APTT in a double-blind,
placebo-controlled trial with crossover design strongly
denies any important in-vivo interaction within the first
3 h after heparin injection. Heparin concentrations as well
as the activities of the two major mediators of heparin
effects remained unchanged, thus ruling out a substantial
depletion of these factors by simultaneously infused
nitroglycerin within the period investigated and with
the drug preparations used.
These results contrast with previous reports which
suggested a nitroglycerin-induced heparin resistance16"81.
However, these observations described an attenuated
heparin effect after several hours or even days of con-
tinuous, intravenous administration of both drugs'7181. A
gradual change in metabolism of heparin or a functional
depletion of AT III or HC II induced by nitroglycerin
after longer periods of simultaneous infusion of both
drugs remains possible. Our in-vivo experiment only
investigated the immediate heparin effect. In the period of
approximately 3 h with a measurable heparin effect after
bolus injection, no interaction with nitroglycerin was
observed.
A dose-response curve may be desirable to exclude
definitely an in-vivo heparin-nitroglycerin interaction. A
longer period of concomitant infusion of both drugs and
higher doses of nitroglycerin might result in an attenuated
heparin effect. However, nitroglycerin concentrations
tested in the in-vitro experiment by far exceed plasma
concentrations achieved by infusion rates used in clinical
practice"31. As a dose-dependent effect was absent in vitro,
we chose to use only one common, therapeutic dosage in
the in-vitro trial (lOOug.min"1) and believe a clinically
relevant effect was sufficiently ruled out. Furthermore, we
were concerned about submitting volunteers to higher
doses of intravenous nitroglycerin.
Another limitation of this study may be the fact that for
ethical reasons we only tested healthy volunteers. Dif-
ferent results in patients with an active thromboembolic
disease such as unstable angina cannot be ruled out. How-
ever, this seems unlikely as a recent investigation in
patients undergoing coronary angioplasty also failed
to show any significant nitroglycerin-induced heparin
resistance1161.
The nitroglycerin preparations used in clinical practice
may be of importance, too. In particular, the solvent
propylene glycol has been# incriminated as the substance
inducing heparin resistance'61. Since the preparation we
used contains polyoxyethylene-40-castoroil as a nonionic
emulsifying agent this could account for the differences in
results. However, this seems unlikely, as both propylene-
glycol-containing and propylene-glycol-free nitroglycerin
preparations have been reported to attenuate heparin
effects'7-81.
In conclusion, an immediate nitroglycerin-induced
heparin resistance with a propylene-glycol-free nitro-
glycerin preparation was absent in vitro and in an in-vivo
trial with healthy volunteers. An attenuation of the anti-
coagulant effect of heparin by nitroglycerin in patients
with active thromboembolic disease or after a prolonged
period of concomitant intravenous administration of
both drugs cannot be ruled out. The clinical importance of
such an interaction calls for further studies.
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